The phage display technique: Advantages and recent patents

Recent Patents on DNA and Gene Sequences

Volumn 5, Issue 2, 2011, Pages 136-148

  de Almeida, Sintia Silva ^a   Magalhães, Aryane Aparecida C ^a   Soares, Siomar de Castro ^a   Zurita Turk, Meritxell ^a   Goulart, Luiz Ricardo ^b   Miyoshi, Anderson ^a   Azevedo, Vasco ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

Author keywords

Antibody library; Patents; Peptide; Phage display; Vaccine

Indexed keywords

ANTIBODY; ENZYME INHIBITOR; EPITOPE; G PROTEIN COUPLED RECEPTOR; HYBRID PROTEIN; RECOMBINANT ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANTIBODY ENGINEERING; ARTICLE; DNA LIBRARY; ENZYME SPECIFICITY; EPITOPE MAPPING; EXPRESSION VECTOR; GENE MAPPING; HUMAN; MOLECULAR WEIGHT; NONHUMAN; OPEN READING FRAME; PEPTIDE ANALYSIS; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SCREENING; SHOTGUN MUTAGENESIS MAPPING; SITE DIRECTED MUTAGENESIS; X RAY CRYSTALLOGRAPHY;

HUMANS; PATENTS AS TOPIC; PEPTIDE LIBRARY; REGISTRIES;

EID: 79959963314     PISSN: 18722156     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221511796392060     Document Type: Article

References (165)

1. Duquesne S, Destoumieux-Garzon D, Peduzzi J, Rebuffat S. Microcins, gene-encoded antibacterial peptides from enterobacteria. Nat Prod Rep 2007 Aug; 24(4): 708-34.
2. Boger DL, Ichikawa S, Tse WC, Hedrick MP, Jin Q. Total syntheses of thiocoraline and BE-22179 and assessment of their DNA binding and biological properties. J Am Chem Soc 2001 Jan 31; 123(4): 561-8.
3. Schwarzer D, Finking R, Marahiel MA. Nonribosomal peptides: from genes to products. Nat Prod Rep 2003 Jun; 20(3): 275-87.
4. Caboche S, Pupin M, Leclere V, Jacques P, Kucherov G. Structural pattern matching of nonribosomal peptides. BMC Struct Biol 2009; 9: 15.
5. Fruton JS. A history of pepsin and related enzymes. Q Rev Biol 2002 Jun; 77(2): 127-47.
6. Scholle JM, White CM. Bivalirudin: a review of pharmacology and therapeutic use. Conn Med 2010 Nov-Dec; 74(10): 595-7.
7. Karagoz GE, Sinnige T, Hsieh O, Rudiger SG. Expressed protein ligation for a large dimeric protein. Protein Eng Des Sel 2011 Feb, 18.
8. Pande J, Szewczyk MM, Grover AK. Phage display: concept, innovations, applications and future. Biotechnol Adv 2010 Nov-Dec; 28(6): 849-58.
9. Zhang Y, Davis JL, Li W. Identification of tribbles homolog 2 as an autoantigen in autoimmune uveitis by phage display. Mol Immunol 2005 Jul; 42(11): 1275-81.
10. Gargir A, Ofek I, Meron-Sudai S, Tanamy MG, Kabouridis PS, Nissim A. Single chain antibodies specific for fatty acids derived from a semi-synthetic phage display library. Biochim Biophys Acta 2002 Jan 15; 1569(1-3): 167-73.
11. Wu Y, Zhang Q, Sales D, Bianco AE, Craig A. Vaccination with peptide mimotopes produces antibodies recognizing bacterial capsular polysaccharides. Vaccine 2010 Sep 7; 28(39): 6425-35.
12. Nakai Y, Nomura Y, Sato T, Shiratsuchi A, Nakanishi Y. Isolation of a Drosophila gene coding for a protein containing a novel phosphatidylserine-binding motif. J Biochem 2005 May; 137(5): 593-9.
13. Fischer C, Buschmann K, Blank M, et al. Identification of a peptide mimicking the binding pattern of an antiphospholipid antibody. Immunobiology 2006; 211(9): 695-9.
14. Agris PF, Marchbank MT, Newman W, et al. Experimental models of protein-RNA interaction: isolation and analyses of tRNA(Phe) and U1 snRNA-binding peptides from bacteriophage display libraries. J Protein Chem 1999 May; 18(4): 425-35.
15. Danner S, Belasco JG. T7 phage display: a novel genetic selection system for cloning RNA-binding proteins from cDNA libraries. Proc Natl Acad Sci USA 2001 Nov 6; 98(23): 12954-9.
16. Cicchini C, Ansuini H, Amicone L, et al. Searching for DNAprotein interactions by lambda phage display. J Mol Biol 2002 Sep 27; 322(4): 697-706.
17. Yonezawa M, Doi N, Kawahashi Y, Higashinakagawa T, Yanagawa H. DNA display for in vitro selection of diverse peptide libraries. Nucleic Acids Res 2003 Oct 1; 31(19):e118.
18. Lim AP, Chan CE, Wong SK, Chan AH, Ooi EE, Hanson BJ. Neutralizing human monoclonal antibody against H5N1 influenza HA selected from a Fab-phage display library. Virol J 2008; 5: 130.
19. Zhang Y, Chen J, Hu Z, et al. Panning and identification of a colon tumor binding peptide from a phage display peptide library. J Biomol Screen 2007 Apr; 12(3): 429-35.
20. Kehoe JW, Kay BK. Filamentous phage display in the new millennium. Chem Rev 2005 Nov; 105(11): 4056-72.
21. Valadon P, Garnett JD, Testa JE, Bauerle M, Oh P, Schnitzer JE. Screening phage display libraries for organ-specific vascular immunotargeting in vivo. Proc Natl Acad Sci USA 2006 Jan 10; 103(2): 407-12.
22. Kanki S, Jaalouk DE, Lee S, Yu AY, Gannon J, Lee RT. Identification of targeting peptides for ischemic myocardium by in vivo phage display. J Mol Cell Cardiol 2011 May; 50(5): 841-8.
23. Molek P, Strukelj B, Bratkovic T. Peptide phage display as a tool for drug discovery: targeting membrane receptors. Molecules 2011; 16(1): 857-87.
24. Misawa S, Kumagai I. Refolding of therapeutic proteins produced in Escherichia coli as inclusion bodies. Biopolymers 1999; 51(4): 297-307.
25. Gershoni JM, Roitburd-Berman A, Siman-Tov DD, Tarnovitski Freund N, Weiss Y. Epitope mapping: the first step in developing epitope-based vaccines. BioDrugs 2007; 21(3): 145-56.
26. Rubinstein ND, Mayrose I, Pupko T. A machine-learning approach for predicting B-cell epitopes. Mol Immunol 2009 Feb; 46(5): 840-7.
27. Banik SSR, Doranz BJ. Mapping complex antibody epitopes. Genet Eng Biotechnol News 2010; 30(2).
28. Van Regenmortel MH. Antigenicity and immunogenicity of synthetic peptides. Biologicals 2001 Sep-Dec; 29(3-4): 209-13.
29. Petersen G, Song D, Hugle-Dorr B, Oldenburg I, Bautz EK. Mapping of linear epitopes recognized by monoclonal antibodies with gene-fragment phage display libraries. Mol Gen Genet 1995 Dec 10; 249(4): 425-31.
30. Fack F, Hugle-Dorr B, Song D, Queitsch I, Petersen G, Bautz EK. Epitope mapping by phage display: random versus gene-fragment libraries. J Immunol Methods 1997 Aug 7; 206(1-2): 43-52.
31. Geysen HM, Mason TJ, Rodda SJ. Cognitive features of continuous antigenic determinants. J Mol Recognit 1988 Feb; 1(1): 32-41.
32. Arap MA. Phage display technology-Applications and innovations. Genet Mol Biol 2005; 28(1): 1-9.
33. Rodi DJ, Makowski L. Phage-display technology--finding a needle in a vast molecular haystack. Curr Opin Biotechnol 1999 Feb; 10(1): 87-93.
34. Moshkovskii SA, Kolesanova EF, Archakov AI. Continuous Bepitope maps of cytochrome P450cam (CYP101) obtained by peptide scanning: correlation to spatial structure. Arch Biochem Biophys 2002 Feb 15; 398(2): 269-74.
35. Landgraf C, Panni S, Montecchi-Palazzi L, et al. Protein interaction networks by proteome peptide scanning. PLoS Biol 2004 Jan; 2(1): E14.
36. Benjamin DC, Perdue SS. Site-Directed Mutagenesis in Epitope Mapping. Methods 1996 Jun; 9(3): 508-15.
37. Hoogenboom HR. Overview of antibody phage-display technology and its applications. Methods Mol Biol 2002; 178: 1-37.
38. Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985 Jun 14; 228(4705): 1315-7.
39. Barbas CF, Burton DR, Scott JK, Silverman GJ. Phage display: a laboratory manual. New York: Cold Spring Harbor Laboratory Press; Cold Spring Harbor; 2000.
40. Sidhu SS. Engineering M13 for phage display. Biomol Eng 2001 Sep; 18(2): 57-63.
41. Paschke M. Phage display systems and their applications. Appl Microbiol Biotechnol 2006 Mar; 70(1): 2-11.
42. Phizicky EM, Fields S. Protein-protein interactions: methods for detection and analysis. Microbiol Rev 1995 Mar; 59(1): 94-123.
43. Hanes J, Pluckthun A. In vitro selection and evolution of functional proteins by using ribosome display. Proc Natl Acad Sci USA 1997 May 13; 94(10): 4937-42.
44. Weisser NE, Hall JC. Applications of single-chain variable fragment antibodies in therapeutics and diagnostics. Biotechnol Adv 2009 Jul-Aug; 27(4): 502-20.
45. Parmley SF, Smith GP. Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene 1988 Dec 20; 73(2): 305-18.
46. McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990 Dec 6; 348(6301): 552-4.
47. Levin AM, Weiss GA. Optimizing the affinity and specificity of proteins with molecular display. Mol Biosyst 2006 Jan; 2(1): 49-57.
48. Smith GP, Scott JK. Libraries of peptides and proteins displayed on filamentous phage. Methods Enzymol 1993; 217: 228-57.
49. Smith GP, Petrenko VA. Phage Display Chem Rev 1997 Apr 1; 97(2): 391-410.
50. Miernyk JA, Thelen JJ. Biochemical approaches for discovering protein-protein interactions. Plant J 2008 Feb; 53(4): 597-609.
51. Vergnon AL, Chu YH. Electrophoretic methods for studying protein-protein interactions. Methods 1999 Oct; 19(2): 270-7.
52. Singh CR, Asano K. Localization and characterization of proteinprotein interaction sites. Methods Enzymol 2007; 429: 139-61.
53. Liu B, Archer CT, Burdine L, Gillette TG, Kodadek T. Label transfer chemistry for the characterization of protein-protein interactions. J Am Chem Soc 2007 Oct 17; 129(41): 12348-9.
54. Sinz A. Investigation of protein-protein interactions in living cells by chemical crosslinking and mass spectrometry. Anal Bioanal Chem 2010 Aug; 397(8): 3433-40.
55. Xu X, Song Y, Li Y, Chang J, Zhang H, An L. The tandem affinity purification method: an efficient system for protein complex purification and protein interaction identification. Protein Expr Purif 2010 Aug; 72(2): 149-56.
56. Williamson MP, Sutcliffe MJ. Protein-protein interactions. Biochem Soc Trans 2010 Aug; 38(4): 875-8.
57. Chavez JD, Liu NL, Bruce JE. Quantification of protein-protein interactions with chemical cross-linking and mass spectrometry. J Proteome Res 2011 Apr 1; 10(4): 1528-37.
58. Herzberg C, Weidinger LA, Dorrbecker B, Hubner S, Stulke J, Commichau FM. SPINE: a method for the rapid detection and analysis of protein-protein interactions in vivo. Proteomics 2007 Nov; 7(22): 4032-5.
59. Selbach M, Mann M. Protein interaction screening by quantitative immunoprecipitation combined with knockdown (QUICK). Nat Methods 2006 Dec; 3(12): 981-3.
60. Blokzijl A, Friedman M, Ponten F, Landegren U. Profiling protein expression and interactions: proximity ligation as a tool for personalized medicine. J Intern Med 2010 Sep; 268(3): 232-45.
61. Konthur Z, Crameri R. High-throughput applications of phage display in proteomic analyses. Targets 2003; 6: 261-70.
62. Zhikui L, Changcun G, Yongzhan N, et al. Screening and identification of recombinant anti-idiotype antibodies against gastric cancer and colon cancer monoclonal antibodies by a phage-displayed single-chain variable fragment library. J Biomol Screen 2010 Mar; 15(3): 308-13.
63. Jager D, Knuth A. Antibodies and vaccines--hope or illusion? Breast 2005 Dec; 14(6): 631-5.
64. Kim SJ, Park Y, Hong HJ. Antibody engineering for the development of therapeutic antibodies. Mol Cells 2005 Aug 31; 20(1): 17-29.
65. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975 Aug 7; 256(5517): 495-7.
66. Aguiar AS, Alves CR, Melgarejo A, Giovanni-de-Simone S. Purification and partial characterization of a thrombin-like/gyroxin enzyme from bushmaster (Lachesis muta rhombeata) venom. Toxicon 1996 May; 34(5): 555-65.
67. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005 Sep; 23(9): 1126-36.
68. Mousli M, Devaux C, Rochat H, Goyffon M, Billiald P. A recombinant single-chain antibody fragment that neutralizes toxin II from the venom of the scorpion Androctonus australis hector. FEBS Lett 1999 Jan 15; 442(2-3): 183-8.
69. Mousli M, Goyffon M, Billiald P. Production and characterization of a bivalent single chain Fv/alkaline phosphatase conjugate specific for the hemocyanin of the scorpion Androctonus australis. Biochim Biophys Acta 1998 Oct 23; 1425(2): 348-60.
70. Licea AF, Becerril B, Possani LD. Fab fragments of the monoclonal antibody BCF2 are capable of neutralizing the whole soluble venom from the scorpion Centruroides noxius Hoffmann. Toxicon. 1996 Aug;34(8): 843-7.
71. Selisko B, Cosio G, Garcia C, Becerril B, Possani LD, Horjales E. Bacterial expression, purification and functional characterization of a recombinant chimeric Fab derived from murine mAb BCF2 that neutralizes the venom of the scorpion Centruroides noxius hoffmann. Toxicon. 2004 Jan;43(1): 43-51.
72. Juarez-Gonzalez VR, Riano-Umbarila L, Quintero-Hernandez V, Olamendi-Portugal T, Ortiz-Leon M, Ortiz E, et al. Directed evolution, phage display and combination of evolved mutants: a strategy to recover the neutralization properties of the scFv version of BCF2 a neutralizing monoclonal antibody specific to scorpion toxin Cn2. J Mol Biol 2005 Mar 11; 346(5): 1287-97.
73. Aubrey N, Muzard J, Christophe Peter J, Rochat H, Goyffon M, Devaux C, et al. Engineering of a recombinant Fab from a neutralizing IgG directed against scorpion neurotoxin AahI, and functional evaluation versus other antibody fragments. Toxicon 2004 Mar 1; 43(3): 233-41.
74. Tamarozzi MB, Soares SG, Marcussi S, Giglio JR, Barbosa JE. Expression of recombinant human antibody fragments capable of inhibiting the phospholipase and myotoxic activities of Bothrops jararacussu venom. Biochim Biophys Acta 2006 Sep;1760(9): 1450-7.
75. He M, Taussig MJ. Ribosome display of antibodies: expression, specificity and recovery in a eukaryotic system. J Immunol Methods 2005 Feb; 297(1-2): 73-82.
76. Francisco JA, Campbell R, Iverson BL, Georgiou G. Production and fluorescence-activated cell sorting of Escherichia coli expressing a functional antibody fragment on the external surface. Proc Natl Acad Sci USA 1993 Nov 15; 90(22): 10444-8.
77. Glockshuber R, Malia M, Pfitzinger I, Pluckthun A. A comparison of strategies to stabilize immunoglobulin Fv-fragments. Biochemistry 1990 Feb 13; 29(6): 1362-7.
78. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001 Jul 26; 345(4): 241-7.
79. Young NM, MacKenzie CR, Narang SA, Oomen RP, Baenziger JE. Thermal stabilization of a single-chain Fv antibody fragment by introduction of a disulphide bond. FEBS Lett 1995 Dec 18; 377(2): 135-9.
80. Holliger P, Prospero T, Winter G. "Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993 Jul 15; 90(14): 6444-8.
81. Iliades P, Kortt AA, Hudson PJ. Triabodies: single chain Fv fragments without a linker form trivalent trimers. FEBS Lett 1997 Jun 16; 409(3): 437-41.
82. Dolezal O, De Gori R, Walter M, et al. Single-chain Fv multimers of the anti-neuraminidase antibody NC10: the residue at position 15 in the V(L) domain of the scFv-0 (V(L)-V(H)) molecule is primarily responsible for formation of a tetramer-trimer equilibrium. Protein Eng 2003 Jan; 16(1): 47-56.
83. Olafsen T, Cheung CW, Yazaki PJ, et al. Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Protein Eng Des Sel 2004 Jan; 17(1): 21-7.
84. Adams GP, McCartney JE, Tai MS, et al. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-cerbB-2 single-chain Fv. Cancer Res 1993 Sep 1; 53(17): 4026-34.
85. Mallender WD, Voss EW, Jr. Construction, expression, and activity of a bivalent bispecific single-chain antibody. J Biol Chem 1994 Jan 7; 269(1): 199-206.
86. Wittel UA, Jain M, Goel A, Chauhan SC, Colcher D, Batra SK. The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs. Nucl Med Biol 2005 Feb; 32(2): 157-64.
87. Korn T, Nettelbeck DM, Volkel T, Muller R, Kontermann RE. Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv. J Gene Med 2004 Jun; 6(6): 642-51.
88. Pack P, Pluckthun A. Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli. Biochemistry 1992 Feb 18; 31(6): 1579-84.
89. Hu S, Shively L, Raubitschek A, et al. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (singlechain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 1996 Jul 1; 56(13): 3055-61.
90. Li SL, Liang SJ, Guo N, Wu AM, Fujita-Yamaguchi Y. Singlechain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth. Cancer Immunol Immunother 2000 Jul; 49(4-5): 243-52.
91. Borsi L, Balza E, Bestagno M, et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 2002 Nov 1; 102(1): 75-85.
92. Cloutier SM, Couty S, Terskikh A, et al. Streptabody, a high avidity molecule made by tetramerization of in vivo biotinylated, phage display-selected scFv fragments on streptavidin. Mol Immunol 2000 Dec; 37(17): 1067-77.
93. Kipriyanov SM, Breitling F, Little M, Dubel S. Single-chain antibody streptavidin fusions: tetrameric bifunctional scFv-complexes with biotin binding activity and enhanced affinity to antigen. Hum Antibodies Hybridomas 1995; 6(3): 93-101.
94. Kipriyanov SM, Little M, Kropshofer H, Breitling F, Gotter S, Dubel S. Affinity enhancement of a recombinant antibody: formation of complexes with multiple valency by a single-chain Fv fragment-core streptavidin fusion. Protein Eng 1996 Feb; 9(2): 203-11.
95. Rheinnecker M, Hardt C, Ilag LL, et al. Multivalent antibody fragments with high functional affinity for a tumor-associated carbohydrate antigen. J Immunol 1996 Oct 1; 157(7): 2989-97.
96. Enever C, Tomlinson IM, Lund J, Levens M, Holliger P. Engineering high affinity superantigens by phage display. J Mol Biol 2005 Mar 18; 347(1): 107-20.
97. Ueno A, Arakawa F, Abe H, et al. T-cell immunotherapy for human MK-1-expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody. Anticancer Res 2002 Mar-Apr; 22(2A): 769-76.
98. Williams A, Baird LG. DX-88 and HAE: a developmental perspective. Transfus Apher Sci 2003 Dec; 29(3): 255-8.
99. Bonetto S, Carlavan I, Baty D. Isolation and characterization of antagonist and agonist peptides to the human melanocortin 1 receptor. Peptides 2005 Nov; 26(11): 2302-13.
100. Gonzalez-Buitrago JM, Gonzalez C. Present and future of the autoimmunity laboratory. Clin Chim Acta 2006 Mar; 365(1-2): 50-7.
101. Pollard KM. Autoantibodies and autoimmunity: Molecular mechanisms in health and disease. Wiley, editor.; 2006.
102. Albright JF, Goldstein RA. Airborne pollutants and the immune system. Otolaryngol Head Neck Surg 1996 Feb; 114(2): 232-8.
103. Smith DA, Germolec DR. Introduction to immunology and autoimmunity. Environ Health Perspect 1999 Oct; 107 Suppl 5: 661-5.
104. Cohen IR. Regulation of autoimmune disease physiological and therapeutic. Immunol Rev 1986 Dec; 94: 5-21.
105. Avrameas S. Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol Today 1991 May; 12(5): 154-9.
106. Nakamura M, Burastero SE, Ueki Y, Larrick JW, Notkins AL, Casali P. Probing the normal and autoimmune B cell repertoire with Epstein-Barr virus. Frequency of B cells producing monoreactive high affinity autoantibodies in patients with Hashimoto's disease and systemic lupus erythematosus. J Immunol 1988 Dec 15; 141(12): 4165-72.
107. Finnern R, Bye JM, Dolman KM, et al. Molecular characteristics of anti-self antibody fragments against neutrophil cytoplasmic antigens from human V gene phage display libraries. Clin Exp Immunol 1995 Dec; 102(3): 566-74.
108. van der Woude FJ, Rasmussen N, Lobatto S, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985 Feb 23; 1(8426): 425-9.
109. Falk RJ, Jennette JC. Wegener's granulomatosis, systemic vasculitis, and antineutrophil cytoplasmic autoantibodies. Annu Rev Med 1991; 42: 459-69.
110. Ward ES, Gussow D, Griffiths AD, Jones PT, Winter G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 1989 Oct 12; 341(6242): 544-6.
111. Braun J, Targan S. Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca. US5691151, 1997.
112. Worman H, Terjung B. Nuclear envelope protein recognized by atypical p-ANCA in patients with inflammatory bowel disease and autoimmune liver diseases. US6627458, 2003.
113. Brunetta P. Method for treating vasculitis. US20060110387, 2006.
114. Oh E, Marcelletti J, Carroll S, Smith K. Methods of diagnosing inflammatory bowel disease. US7759079, 2010.
115. Bach JF. Therapeutic monoclonal antibodics. Ann Pharm Fr 2006 Sep; 64(5): 308-11.
116. Hoet RM, Cohen EH, Kent RB, et al. Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity. Nat Biotechnol 2005 Mar; 23(3): 344-8.
117. Desiderio A, Franconi R, Lopez M, et al. A semi-synthetic repertoire of intrinsically stable antibody fragments derived from a single-framework scaffold. J Mol Biol 2001 Jul 13; 310(3): 603-15.
118. Griffiths AD, Hoogenboom HR, Marks JD, Mccafferty J, Winter GP, Grigg GW. Production of anti-self antibodies from antibody segment repertoires and displayed on phage. EP1696031, 2006.
119. Gao C, Mao S, Lo CH, Wirsching P, Lerner RA, Janda KD. Making artificial antibodies: a format for phage display of combinatorial heterodimeric arrays. Proc Natl Acad Sci USA 1999 May 25; 96(11): 6025-30.
120. Kwasnikowski P, Kristensen P, Markiewicz WT. Multivalent display system on filamentous bacteriophage pVII minor coat protein. J Immunol Methods 2005 Dec 20; 307(1-2): 135-43.
121. Khalil AS, Ferrer JM, Brau RR, et al. Single M13 bacteriophage tethering and stretching. Proc Natl Acad Sci USA 2007 Mar 20; 104(12): 4892-7.
122. Løset GÅ. PVII Phage display. EP20080787356, 2010.
123. Day LA, Marzec CJ, Reisberg SA, Casadevall A. DNA packing in filamentous bacteriophages. Annu Rev Biophys Biophys Chem 1988; 17: 509-39.
124. Marvin DA, Hale RD, Nave C, Helmer-Citterich M. Molecular models and structural comparisons of native and mutant class I filamentous bacteriophages Ff (fd, f1, M13), If1 and IKe. J Mol Biol 1994 Jan 7; 235(1): 260-86.
125. Cabilly S. The basic structure of filamentous phage and its use in the display of combinatorial peptide libraries. Mol Biotechnol 1999 Sep; 12(2): 143-8.
126. Glucksman MJ, Bhattacharjee S, Makowski L. Three-dimensional structure of a cloning vector. X-ray diffraction studies of filamentous bacteriophage M13 at 7 A resolution. J Mol Biol 1992 Jul 20; 226(2): 455-70.
127. Felici F, Castagnoli L, Musacchio A, Jappelli R, Cesareni G. Selection of antibody ligands from a large library of oligopeptides expressed on a multivalent exposition vector. J Mol Biol 1991 Nov 20; 222(2): 301-10.
128. Riechmann L, Holliger P. The C-terminal domain of ToIA is the coreceptor for filamentous phage infection of E-coli. Cell 1997 Jul 25; 90(2): 351-60.
129. Specthrie L, Bullitt E, Horiuchi K, Model P, Russel M, Makowski L. Construction of a microphage variant of filamentous bacteriophage. J Mol Biol 1992 Dec 5; 228(3): 720-4.
130. Greenwood J, Willis AE, Perham RN. Multiple display of foreign peptides on a filamentous bacteriophage. Peptides from Plasmodium falciparum circumsporozoite protein as antigens. J Mol Biol 1991 Aug 20; 220(4): 821-7.
131. Willis AE, Perham RN, Wraith D. Immunological properties of foreign peptides in multiple display on a filamentous bacteriophage. Gene 1993 Jun 15; 128(1): 79-83.
132. Smith GP. Surface display and peptide libraries. Cold Spring Harbor Laboratory, April 4-7, 1992. Proc Gene 1993 Jun 15; 128(1): 1-144.
133. English J, Schmidt F, Smith G, Morris R, Bishop-hurley S, inventors; Phage display selection of anti fungal peptides. US7811994, 2010.
134. Caberoy NB, Alvarado G, Li W. Identification of calpain substrates by ORF phage display. Molecules 2011; 16(2): 1739-48.
135. Garufi G, Minenkova O, Lo Passo C, Pernice I, Felici F. Display libraries on bacteriophage lambda capsid. Biotechnol Annu Rev 2005; 11: 153-90.
136. Caberoy NB, Zhou Y, Alvarado G, Fan X, Li W. Efficient identification of phosphatidylserine-binding proteins by ORF phage display. Biochem Biophys Res Commun 2009 Aug 14; 386(1): 197-201.
137. Caberoy NB, Zhou Y, Jiang X, Alvarado G, Li W. Efficient identification of tubby-binding proteins by an improved system of T7 phage display. J Mol Recognit 2010 Jan-Feb; 23(1): 74-83.
138. Li W, Jiang X, Caberoy NB. Open-Reading-Frame (ORF) Phage Display. WO2010030425, 2010.
139. Carragher NO. Calpain inhibition: a therapeutic strategy targeting multiple disease states. Curr Pharm Des 2006; 12(5): 615-38.
140. Zatz M, Starling A. Calpains and disease. N Engl J Med 2005 Jun 9; 352(23): 2413-23.
141. Jia Z, Petrounevitch V, Wong A, et al. Mutations in calpain 3 associated with limb girdle muscular dystrophy: analysis by molecular modeling and by mutation in m-calpain. Biophys J 2001 Jun; 80(6): 2590-6.
142. Chen CJ, Nguyen T, Shively JE. Role of calpain-9 and PKC-delta in the apoptotic mechanism of lumen formation in CEACAM1 transfected breast epithelial cells. Exp Cell Res 2010 Feb 15; 316(4): 638-48.
143. Davis TL, Walker JR, Finerty PJ, Jr., Mackenzie F, Newman EM, Dhe-Paganon S. The crystal structures of human calpains 1 and 9 imply diverse mechanisms of action and auto-inhibition. J Mol Biol 2007 Feb 9; 366(1): 216-29.
144. Trinchese F, Fa M, Liu S, et al. Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease. J Clin Invest 2008 Aug; 118(8): 2796-807.
145. Lee HY, Morton JD, Robertson LJ, et al. Evaluation of a novel calpain inhibitor as a treatment for cataract. Clin Experiment Ophthalmol 2008 Dec; 36(9): 852-60.
146. Dias-Neto E, Nunes DN, Giordano RJ, et al. Next-generation phage display: integrating and comparing available molecular tools to enable cost-effective high-throughput analysis. PLoS One 2009; 4(12): e8338.
147. Di Niro R, Mesin L, Raki M, et al. Rapid generation of rotavirusspecific human monoclonal antibodies from small-intestinal mucosa. J Immunol 2010 Nov 1; 185(9): 5377-83.
148. Noren KA, Noren CJ. Construction of high-complexity combinatorial phage display peptide libraries. Methods 2001 Feb; 23(2): 169-78.
149. Chang CC, Chen TT, Cox BW, et al. Evolution of a cytokine using DNA family shuffling. Nat Biotechnol 1999 Aug; 17(8): 793-7.
150. Crameri A, Raillard SA, Bermudez E, Stemmer WP. DNA shuffling of a family of genes from diverse species accelerates directed evolution. Nature 1998 Jan 15; 391(6664): 288-91.
151. Stoop AA, Jespers L, Lasters I, Eldering E, Pannekoek H. Highdensity mutagenesis by combined DNA shuffling and phage display to assign essential amino acid residues in protein-protein interactions: application to study structure-function of plasminogen activation inhibitor 1 (PAI-I). J Mol Biol 2000 Sep 1; 301(5): 1135-47.
152. Karrer E, Bass SH, Whalen R, Patten PA. Antibody diversity generation. US20080207459, 2008.
153. Stemmer WPC. Methods for in vitro recombination. US5605793, 1997.
154. Stemmer WPC, Crameri A. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination. US5811238, 1998.
155. Stemmer WPC, Crameri A. DNA mutagenesis by random fragmentation and reassembly. US5830721, 1998.
156. Punnonen J, Bass SH, Whalen RG, Howard R, Stemmer WPC. Antigen library immunization. US6541011, 2003.
157. Punnonen J, Stemmer WPC, Whalen RG, Howard R. Genetic Vaccine Vector Engineering. US20010006950, 2001.
158. Punnonen J, Stemmer WPC, Whalen RG, Howard RJ. Optimization of immunomodulatory properties of genetic vaccines. US7390619, 2008.
159. Arnold F, Shao Z, Volkov A. Method for creating polynucleotide and polypeptide sequences. US6537746, 2003.
160. Jesper V. An In vitro method for construction of a DNA library. WO199841653, 1998.
161. Pati S, Zarling DA. Sequence alterations using homologous recombination. WO199842727, 1998.
162. Borchert TV, Kretzschmar T, Cherry JR. Method for constructing a library using DNA shuffling. WO199841622, 1998.
163. Hufton SE, Finlay WJJ. Compatible display vector systems. US20100120634, 2009.
164. Miller LK. Baculovirus expression vectors. US5244805, 1993.
165. Makela AR, Ernst W, Grabherr R, Oker-Blom C. Creation of baculovirus display libraries. Cold Spring Harb Protoc 2010 Mar; 2010(3): pdb prot5393.